InvestorsHub Logo
Followers 17
Posts 1275
Boards Moderated 0
Alias Born 01/26/2013

Re: None

Wednesday, 08/03/2016 11:02:02 PM

Wednesday, August 03, 2016 11:02:02 PM

Post# of 1036
Fantastic Quarter - bright future ahead.

1. Strong Q2 indicates fast market adaptation of ILUVIEN. The high growth indicates ILUVIEN going to be the SOC for DME in few years.

2. Great positive discussion with FDA for ILUVIEN's other indication - one Phase-3 needed and preparation on the way. Great new potential

3. $15M quarterly revenue would be the breakeven ..which could come just in two more quarters. IMO

4. 2017 will be a whole new picture....can't wait for the guidance tomorrow.

Huge upside potential... big pharma will buy this little gem.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ALIM News